Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 439171, 7 pages
Review Article

Multiparametric MRI in Biopsy Guidance for Prostate Cancer: Fusion-Guided

1Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1210, USA
2Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1210, USA

Received 3 April 2014; Revised 9 June 2014; Accepted 11 June 2014; Published 13 July 2014

Academic Editor: Barıs Turkbey

Copyright © 2014 Jason T. Rothwax et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Prostate cancer (PCa) is the most common solid-organ malignancy among American men and the second most deadly. Current guidelines recommend a 12-core systematic biopsy following the finding of an elevated serum prostate-specific antigen (PSA). However, this strategy fails to detect an unacceptably high percentage of clinically significant cancers, leading researchers to develop new, innovative methods to improve the effectiveness of prostate biopsies. Multiparametric-MRI (MP-MRI) has emerged as a promising instrument in identifying suspicious regions within the prostate that require special attention on subsequent biopsy. Fusion platforms, which incorporate the MP-MRI into the biopsy itself and provide active targets within real-time imaging, have shown encouraging results in improving the detection rate of significant cancer. Broader applications of this technology, including MRI-guided focal therapy for prostate cancer, are in early phase trials.